NDAORALTABLET
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
ZYFLO (zileuton) by Chiesi is 5-lipoxygenase inhibitors [moa]. Approved for 5-lipoxygenase inhibitor [epc]. First approved in 1996.
Drug data last refreshed 3h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYFLO (zileuton) is an oral 5-lipoxygenase inhibitor approved in 1996 for the treatment of asthma. It works by blocking leukotriene synthesis, reducing airway inflammation and bronchoconstriction in asthma patients. This small molecule targets a specific inflammatory pathway distinct from inhaled corticosteroids and beta-agonists.
$0.003BPart D
LOE ApproachingDeclining
Mature product with minimal market penetration and declining claims signals a niche, stable-to-contracting team focused on retention rather than growth initiatives.
Mechanism of Action
5-Lipoxygenase Inhibitors
Pharmacologic Class:
5-Lipoxygenase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Started Jan 2014
2 enrolled
Chronic Myelogenous Leukemia
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
Started Dec 2003
140 enrolled
Lung Cancer
Career Relevance
Working on ZYFLO offers experience in mature product management and niche market defense rather than launch innovation or rapid growth scaling. Roles are primarily commercial-focused, with limited upside but stable, predictable responsibilities suited to professionals seeking specialized asthma expertise.
Worked on ZYFLO at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.